<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  1     INDICATIONS AND USAGE<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Zortress is indicated for the prophylaxis of organ rejection in adult patients: <BR>                           Kidney transplant: at low-moderate immunologic risk. (1.1) Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids.<BR>                           Liver transplant: Administer no earlier than 30 days post-transplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. (1.2, 5.5)<BR>                        <BR>                        Limitations of Use (1.3)<BR>                        Safety and efficacy has not been established in the following:<BR>                        <BR>                           Kidney transplant patients at high immunologic risk.<BR>                           Recipients of transplanted organs other than kidney or liver<BR>                           Pediatric patients (<18 years) <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1     Prophylaxis of Organ Rejection in Kidney Transplantation<BR>                     <BR>                        Zortress is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. [See Clinical Studies (14.1)] Zortress is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. Therapeutic drug monitoring of everolimus and cyclosporine is recommended for all patients receiving these products. [See <BR>                           Dosage and Administration <BR>                           (2.2 and 2.3)]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2     Prophylaxis of Organ Rejection in Liver Transplantation<BR>                     <BR>                        <BR>                           Zortress is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. Zortress is to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [See Warnings and Precautions (5.5) and Clinical Studies (14.2)]. Therapeutic drug monitoring of everolimus and tacrolimus is recommended for all patients receiving these products. [See Dosage and Administration (2.3 and 2.5)]<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.3     Limitations of Use<BR>                     <BR>                        The safety and efficacy of Zortress has not been established in the following populations:<BR>                             Kidney transplant patients at high immunologic risk<BR>     Recipients of transplanted organs other than kidney and liver [See Warnings and Precautions (5.7)]<BR>     Pediatric patients (<18 years).<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>